Kaken Pharmaceutical Co., Ltd.
KKPCF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $138,506 | $18,867,000 | $18,045,000 | $24,618,000 |
| % Growth | -99.3% | 4.6% | -26.7% | – |
| Cost of Goods Sold | $59,360 | $8,995,000 | $8,705,000 | $9,528,000 |
| Gross Profit | $79,146 | $9,872,000 | $9,340,000 | $15,090,000 |
| % Margin | 57.1% | 52.3% | 51.8% | 61.3% |
| R&D Expenses | $42,520 | $5,382,000 | $8,168,000 | $4,584,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $35,348 | $4,474,000 | $5,289,000 | $4,662,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2,000 | $269,000 | $3,000 |
| Operating Expenses | $77,868 | $9,858,000 | $13,726,000 | $9,249,000 |
| Operating Income | $1,278 | $14,000 | -$4,386,000 | $5,841,000 |
| % Margin | 0.9% | 0.1% | -24.3% | 23.7% |
| Other Income/Exp. Net | $5,401 | $394,000 | -$2,200,000 | $945,000 |
| Pre-Tax Income | $6,679 | $408,000 | -$6,586,000 | $6,786,000 |
| Tax Expense | $1,805 | $137,000 | -$1,356,000 | $1,897,000 |
| Net Income | $4,874 | $271,000 | -$5,230,000 | $4,889,000 |
| % Margin | 3.5% | 1.4% | -29% | 19.9% |
| EPS | 0.13 | 7.12 | -133.99 | 129.09 |
| % Growth | -98.2% | 105.3% | -203.8% | – |
| EPS Diluted | 0.13 | 7.12 | -133.99 | 129.09 |
| Weighted Avg Shares Out | 37,868 | 38,043 | 39,032 | 37,874 |
| Weighted Avg Shares Out Dil | 37,868 | 38,043 | 39,032 | 37,874 |
| Supplemental Information | – | – | – | – |
| Interest Income | $500 | $298 | $33,000 | $261,000 |
| Interest Expense | $74 | $69 | $0 | $0 |
| Depreciation & Amortization | $5,638 | -$16,000 | $638,500 | $688,250 |
| EBITDA | $12,371 | $0 | -$3,749,500 | $6,532,250 |
| % Margin | 8.9% | 0% | -20.8% | 26.5% |